Review Article

Local therapies for managing oligometastatic breast cancer: a review

Hina Saeed[1]^, Anna M. Kirby[2]

[1]Department of Radiation Oncology, Medical College of Wisconsin, Milwaukee, WI, USA; [2]Department of Clinical Oncology, Royal Marsden Hospital and Institute of Cancer Research, Sutton, London, UK
Contributions: (I) Conception and design: Both authors; (II) Administrative support: Both authors; (III) Provision of study material or patients: Both authors; (IV) Collection and assembly of data: Both authors; (V) Data analysis and interpretation: Both authors; (VI) Manuscript writing: Both authors; (VII) Final approval of manuscript: Both authors.
Correspondence to: Hina Saeed. Department of Radiation Oncology, Medical College of Wisconsin, Milwaukee, WI, USA.
Email: hisaeed@mcw.edu.

Abstract: The hypothesis that oligometastatic disease (OMD) may be cured through local eradication therapies has precipitated increasing research into the use of locally ablative therapies (LAT) for these patients. Advances in molecular biology have confirmed the presence of clinically and radiographically suspected oligometastatic state at the genomic level. At the same time, technological advances in different treatment modalities (primarily radiation and surgery) have allowed the administration of ablative doses to a broader spectrum of metastatic lesions. Despite increasing efficacy of modern systemic therapies, they are seldom curative. There is growing interest in identifying patients with truly oligometastatic breast cancer (OMBC) and in developing predictive biomarkers to determine which patients are more likely to benefit from LAT. In this review, we discuss data specific to the OMBC setting, the recent advances in understanding oligometastasis biology, the natural history of OMBC including diagnosis and classification, the theoretical basis for LAT, retrospective and prospective data supporting LAT, outcomes associated with LAT and ongoing prospective randomized trials designed to compare LAT and standard of care (SOC) therapies. We especially focus on LAT, primarily surgery and non-invasive stereotactic body radiation therapy (SBRT) for OMBC with references to other tumor types when these other tumor types inform OMBC treatment.

Keywords: Local; ablation; oligometastases; breast cancer

Introduction

Contemporary insights into carcinogenesis have resulted in recognition of cancer as a multi-step process or a metastatic cascade rather than a binary phenomenon (1,2). This led to Hellman and Weichselbaum describing a new entity, "oligometastatic disease" (OMD) in 1995, as an intermediate state (limited in number of metastases and involved organs) in the spectrum of metastatic disease (3).

Recognition of oligometastatic breast cancer (OMBC) as "potentially curable" and a distinctive subset of metastatic breast cancer (MBC) together with knowledge of an invasion-metastases cascade has given rise to the idea that early eradication of metastases using local ablative therapies (LAT) could avoid subsequent dissemination (4). OMD can be classified by the timing of its appearance in relation to the primary disease and/or systemic therapies. Each OMD scenario will have a different standard-of-care approach and aim such that assessment of added benefits of LATs will

require different endpoints (5).

Common sites of metastases for OMBC include bone, lung, liver, brain and lymph nodes (LN). LAT for OM disease have mainly involved surgery and/or stereotactic body radiation therapy (SBRT) with evolving modalities including radiofrequency ablation (RFA) and transarterial chemoembolization (TACE). Against a background of increasingly complex systemic therapy (ST) approaches and improved survival, evaluating the added benefit of LATs in OMBC patients remains challenging.

This manuscript focuses on the current understanding of OMD, efforts to identify and classify OMBC, and published data on outcomes following LAT for OMBC whilst highlighting aspects where gaps in knowledge exist. A literature search was conducted in PubMed/MEDLINE for the terms "breast cancer" and "oligomet" to retrieve all relevant English-language articles. Citation chasing was conducted by analyzing the bibliography of references (backwards citation chasing) and through Google Scholar (forward citation chasing) (6).

Natural history of OMD

The definition of OMD comprises both the attempt to characterize those patients who are truly oligo- rather than polymetastatic such that LAT could influence the natural history of the disease, and the anatomical localization of oligometastases in order to be able to target them with LATs. Both aspects are discussed here.

Definition of OMD state

Based on clinical experience, Hellman and Weichselbaum described the concept of oligometastases as a clinically significant intermediate state of distant spread, reflecting disease with a low, slow and late metastatic spreading capacity (2,3). Since then, the concept has continued to mature and evolve.

There have been ongoing discussions around the number of metastases to be included under the term "oligometastasis". Published series have generally included up to 3–5 metastases in up to two organ systems (7-10). With variations in reporting, imaging sensitivity and absence of biological basis for lesion number or size, the maximum number of OMs in which use of LAT for all OMs would yield a clinical benefit over and above a change of ST is yet to be determined (11). As per the ASTRO-ESTRO consensus statement, an oligometastatic patient can be defined as an individual in which all the tumor locations are amenable to safe ablation with curative intent.

From a molecular standpoint, studies are increasingly confirming the basis for the OMD concept (12). Cancer progression is a multi-step process and, biologically, only a tiny proportion of cancer cells have clonogenic potential to successfully colonize secondary organs (1,13). With technology allowing increasingly granular resolution at the single cell genomic level, several hallmarks of cancer evolution have come into light: genotypic heterogeneity, immortality, presence of circulating tumor cells (CTCs) or circulating tumor DNA (ctDNA), dormancy, autophagy and phenotypic plasticity for resisting hostile selective pressures at distant sites. Somewhere during this transit, the cells presumably have not yet reached fuller metastatic potential and remain localized to a select few sites that provide a favorable niche (14-20). Additionally, unique mutations harbored by the primary tumor and metastatic lesions imply an ongoing branched pattern in genetic evolution once metastasis has occurred (21). At times, a solitary metastasis can be present for years as a single site of disease before subsequently seeding more widespread metastases and/or reseeding the primary tumor (22-25).

Some studies suggest that oligometastatic progression may be regulated at least in part by epigenetic alterations and potentially by microRNA (19–22 nucleotides regulating gene expression). MicroRNA profiling has allowed a more rigorous examination of the genomic underpinnings of a cell's metastatic potential. Analysis of a select panel of prospectively obtained microRNAs from the metastatic tumors of a cohort of patients with OMD subjected to radiotherapy revealed a distinct clustering of oligometastatic versus polymetastatic phenotypes with notable enrichment of microRNA200 in the polymetastatic samples (26). Other studies have also shown differential microRNA expression in slow versus rapid-progressing metastatic disease, with several of these implicated in metastatic cascade (27,28). In a cohort of MBC patients, microRNA expression profiling has been able to independently discriminate between oligo and polymetastatic breast cancer (29) thus supporting the concept of OMBC as a genetically distinct entity (28).

As yet however, in the clinic, there remain no validated molecular biomarkers that differentiate between the oligometastatic and polymetastatic states (11). In the meantime, rapid advances in imaging that allow identification of smaller metastatic deposits increase the likelihood of correctly identifying the oligometastatic state (30).

Anatomical localization of OMD

OMBC constitutes between 1% and 20% of all MBCs according to published literature although, with more recent advances in ST, the truth is likely to lie towards the top of that range (31,32). Identifying these patients is crucial both to offering local treatment with potentially curative intent and to optimizing resource utilization. Patients with a tendency towards polymetastatic disease will not benefit from LAT and should instead be considered for change of systemic approach.

Radiological identification of patients with OMBC is challenging. Most published series refer to an era before modern imaging, and thus many patients were probably under-staged, potentially leading to underestimation of the longer-term benefits of aggressive local management. Modern imaging with improved sensitivity and specificity has the potential to more accurately identify OMD, some of it in evolution to polymetastatic disease and some destined for indolent, non-progressive behavior. There remain, however, limitations in the sensitivity of modern imaging modalities. The risk of false positives also exists as validation by biopsy of multiple visualized lesions is usually impractical.

Anatomic sites for extracranial breast cancer metastases include bone, viscera (particularly lung and liver) and LN. For extracranial MBC, ^{18}F-FDG-PET/CT is an easily accessible imaging diagnostic tool with sensitivity of 90–94% and an accuracy rate of 83–90% (33,34). With bone being the first site of metastases for almost half of MBC patients and the most common site of metastases for estrogen receptor positive (ER+) disease, accurate identification of this subset of OMBC is critical. With bone-confined MBC, the natural history is usually characterized by an indolent course (35) with up to 20% alive at 5 years (36). Notably, solitary bone metastases have been significantly associated with prolonged OS (37). ^{18}F-FDG-PET/CT is more specific for metastatic bone disease than nuclear medicine bone scanning (38) and therefore is the preferred modality (39).

The incidence of lung metastases in MBC patients ranges between 23–36% with 6–10% of patients having lung-only metastases. A population-based study showed that increasing age, black race, high grade, human epidermal growth factor receptor 2 (HER2)-positive or triple-negative (TN) tumors were more likely to be associated with lung metastases (40). ^{18}F-FDG PET/CT remains the preferred approach for diagnosing pulmonary metastases in OMBC (41).

In liver, the sensitivity of ^{18}F-FDG-PET is limited for small metastases (<1 cm in diameter) due to liver motion during image acquisition and poor spatial resolution. MRI is superior for depicting and characterizing liver lesions compared to ultrasound, CT and ^{18}F-FDG PET/CT (42,43). The incidence of liver metastases in MBC patients is 40–50%. Growing evidence indicates that HER2-positive or TN tumors are more likely to be associated with liver metastases (44).

In relation to nodal disease, up to 5% of patients with early-stage breast cancer have regional nodal recurrence after breast conservation treatment (45-47). LAT appear effective in locally controlling LN oligometastases (48). Consequently, their identification through ultrasound, CT or ^{18}F-FDG-PET/CT is vital to improve OMBC outcomes.

Whole body-MRI (WB-MRI), like ^{18}F-FDG-PET/CT offers the advantage of multi-organ evaluation. Although some studies have emphasized the sensitivity of WB-MRI, one has also highlighted its poor specificity (82% of lesions on 1.5T WB-MRI DWI considered false-positive versus 11% on ^{18}F-FDG PET/CT) (49). Another study suggested equivalence of these techniques (WB-MRI versus ^{18}F-FDG PET/CT sensitivity 93% versus 91% and specificity 86% versus 90%) (50). Combined PET/MR imaging yields better sensitivity for liver and possibly bone metastases (41). ^{18}F-FDG PET/MR offers better classification of malignant versus benign lesions (51) compared with ^{18}F-FDG PET/CT, an important consideration in disease recurrence. Importantly, both WB-MRI and PET/MR, as compared to ^{18}F-FDG PET/CT, have accessibility and financial implications.

Although intracranial metastases occur in 0.4% of patients at presentation, this increases to ~8% (52) when other extracranial metastases are present, indicating that imaging (brain MRI) is warranted in the presence of extracranial disease (52) and/or suspicious neurologic symptoms. The risk of symptomatic intracranial metastases and a shorter brain metastases-free survival is more pronounced in TN and HER2-positive tumors compared with luminal or HER2-negative subtypes, potentially lowering the threshold for imaging (53-55). Other risk factors for the development of brain metastases include young age at diagnosis, presence of lung metastases, and short disease-free interval (DFI) (56-58). There is a suggestion that brain-only MBC, regardless of histology, has a better prognosis (59) supporting the use of a more aggressive local approach in these patients.

Imaging approaches should be tailored to the location and extent of OMBC at different points in the disease

trajectory such as initial diagnosis, response assessment and surveillance. From the perspective of response evaluation to systemic therapies, ^{18}F-FDG-PET/CT has the unique advantage of identifying persistent or progressive OMBC early on (39).

Oligocare (NCT03818503), a joint initiative between the European Society for Radiotherapy and Oncology (ESTRO) and the EORTC is a prospective, large-scale observational basket study for OMD patients. Optimal standardized quality imaging approaches are essential to interpret the data. Current evidence-based imaging guidance for Oligocare patients indicates that ^{18}F-FDG PET/CT is favored in breast cancer (with WB-MRI or PET/MR as alternatives) but needs supplementing with liver-specific MRI. At times, technologically 'advanced' imaging with better sensitivities and specificities may be preferred over standard imaging modalities. European Society of Medical Oncology (ESMO) and National Comprehensive Cancer Network (NCCN) provide imaging recommendations in the setting of high risk new primary or recurrent disease (39).

Classification of OMBC

Various scenarios of OMBC can present with similar imaging features and yet differ substantially from a clinical management perspective. Failure to consider the entire oncologic history could substantially affect clinical outcomes (60). Moving beyond the simplistic definition of oligometastasis, a recently published classification system based on five questions about the patient's clinical history and disease burden, provides guidance to highlight the existence of three broad categories of OMD: *de-novo*, repeat and induced. These categories can further be sub-divided into an array of nine clinical states, expanding upon clinical concepts that are already gaining momentum (5). These clinical states will each have distinct prognoses requiring different treatment approaches to accomplish unique goals and endpoints. Although the most frequently defined endpoints in OMD are local control (LC), overall survival (OS), progression-free survival (PFS), deferral of ST, maintenance of current ST and quality of life (QoL) (61), a recent consensus document has expanded on this spectrum providing guidance to match a specific scenario with a relevant endpoint (11).

Management of OMBC

Based on cohort studies, the resection or ablation of OMD

has become standard therapy for several tumor sites such as colorectal cancer and renal cell carcinoma (62). In the case of OMBC, the goals for local management are distinct from those for MBC where local therapies are used for palliation or debulking. There is some evidence that women with low-volume OMBC may experience cure or improved PFS if all the tumor cells can be removed or treated effectively (32,63-67). In a prospective cohort of OMBC patients, OS of almost 50% was reported at 6 years (68). Recent developments in targeted systemic therapies might ultimately make the role of LC of residual and/or resistant lesions in OMBC more important. A unique advantage of local treatment is the subsequent reduction in the reservoir of potentially resistant clones especially in the context of ST induced selection pressure and prior to the clones' widespread dissemination (69-71).

Local management of the primary

The majority of current data pertaining to the local treatment of the primary site come from MBC in general. Several retrospective studies suggest an OS benefit from local management of the primary tumor in MBC (72-75). Potential reasons for this included selection bias (younger patients, better performance status, smaller tumor, more ER+ disease, lower metastatic burden), reversal of tumor-induced immunosuppression (76), decreased overall tumor burden and potentially resistant cell lines, removal of source as seeding new metastases (77), and increased chemosensitivity due to surgery-induced angiogenesis in distant disease sites. A notable limitation of these reviews includes lack of details around local and systemic therapies and therefore reduced applicability to current ST practice (73,78-81). By contrast, an analysis of two prospective non-interventional studies of MBC showed no difference in outcomes with the addition of local therapy to systemic management albeit that a subgroup analysis suggested a better prognosis following LAT for OMBC (82). Similar results were shown by a small prospective registry study (83). While the Indian prospective study showed no survival benefit with locoregional therapy, even for patients with limited disease (84), the Turkish study showed a benefit but was criticized for an unbalanced randomization (85). Most recently, the ECOG 2108 study presented at American Society of Clinical Oncology (ASCO) 2020 showed no survival or QoL benefit with local therapy in MBC (86). These studies together suggest that local treatment of the primary is of questionable survival benefit in MBC. This is in

contrast to the prostate cancer setting where the randomized phase 3 STAMPEDE trial found that local radiation treatment of the primary prostate cancer alone, without locally ablative therapy to the metastases, improved OS in patients with a low metastatic burden, but not in those with a high metastatic burden, compared with androgen deprivation therapy only (87). Further well-designed randomized controlled trials (RCTs) in the OMBC setting may now be challenging given the large numbers required to demonstrate a survival advantage from radical management of primary disease in the OMBC setting. LC however remains an important endpoint such that many institutions would still recommend radical treatment of locoregional disease, particularly in the OMBC (as opposed to MBC) setting.

Locally ablative therapies (LAT)

Advances in treatment modalities have made it theoretically possible to ablate all detectable metastases in OMBC (88). Ablative treatment options for commonly treated sites in OMBC include surgery, SBRT, RFA and TACE. These modalities can be grouped together under the umbrella of LAT. It should be noted that the rapid adoption of LAT has occurred in the absence of randomized phase III evidence such that it remains challenging to select the population of patients in whom LATs have the greatest potential to prolong survival (89). As stated earlier the ESTRO-ASTRO consensus is that LATs be considered for patients for whom complete and safe ablation of all metastases is possible and in whom the pertinent oncologic scenario has been taken into account.

Management of extracranial metastases
Surgery
Bone is one of the most frequent sites of early metastatic disease in breast cancer and, as such, the presence of OMD disease in bone might represent the more indolent part of the metastatic process and therefore a point at which LAT may be able to influence the natural history of the disease. In a series of 115 MBC patients undergoing surgery (majority in the spine or proximal extremity), multivariate analysis showed that patients with solitary bone metastases had better survival compared to patients who had both bone and visceral disease (median OS of 65 versus 13 months) with no impact due to age or extent of surgery (90). Although sternal metastases are uncommon, they might be an extension of internal mammary LN eroding into the bone and as such have a better prognosis, particularly if

solitary. In a small series of 9 patients with solitary sternal metastases and radical resection, a median survival of 30 months was reported (91). A retrospective review of 17 patients at Royal Marsden concluded that curative-intent *en-bloc* sternal resection for solitary sternal/parasternal breast cancer recurrence can provide good durable LC (77% at 5 years) and pain relief (92).

With respect to liver-directed LATs systematic reviews, retrospective cohorts and case series in MBC give conflicting results (66,93-95). This is also the case for OMBC. In a case-control study of 102 patients (only bone and ≤4 liver metastases allowed), half of whom underwent concurrent ST and liver resection and half of whom were matched non-surgery patients, there was a 3-fold higher risk of death on multivariate analysis without surgery (3-year survival of 50% versus 80% in non-surgery versus surgery cohort) (96). Predictive factors for better outcomes included ≤1 course of chemotherapy and absence of bone metastases. Other additional positive factors include a DFI of >2 years, solitary liver metastasis, absence of extrahepatic disease (except for isolated lung and bony metastasis), good systemic response, negative surgical margins and hormone responsiveness (97,98).

Similarly, there are no high-quality prospective trials to provide guidance for pulmonary resection in breast cancer (99). Historical cohort and case series have shown a large range in 5-year OS outcomes (36–62%) (64,100-105). A recent systematic review and meta-analysis of 15 retrospective and 1 prospective cohort studies encompassing almost 2,000 MBC patients with isolated pulmonary metastases undergoing local resection with or without concurrent ST showed a pooled 5-year OS of 46% (106). Predictive factors for improved OS included solitary pulmonary metastasis (pooled HR 1.30 for OS). Limitations include less than 5-year follow-up for majority of the studies, variable sample sizes, heterogeneous population and selective good performance status patients. Notably, several studies leaned towards favoring oligometastatic phenotype by excluding patients with extra-pulmonary metastases or even bilateral pulmonary metastases. Other additional positive factors include a DFI >3 years, solitary metastasis, hormone responsiveness, small metastases, and complete resection (32,63).

Radiotherapy
Given the number of organ systems that can be involved in OMBC and the invasive nature of surgery, there has been an effort to develop minimally or non-invasive methods for delivering LAT. SBRT or stereotactic ablative radiotherapy

(SABR) is an external radiotherapy technique that delivers highly conformal ablative doses [biologically effective dose (BED_{10}) >100 Gy] under precise image guidance. The technique is performed on an outpatient basis and involves only a few sessions (usually between 3 and 5), with little acute toxicity. Advances such as MR Linac and Cyberknife have the potential to further reduce toxicity with even tighter margins. SBRT is convenient and has no detrimental impact on QoL (107-109). Discussions around target volume, dose and treatment platform are beyond the scope of this review (110,111).

The majority of data supporting the use of SBRT come from retrospective and prospective non-randomized, mostly single arm studies (see *Table 1*).

(I) Studies of mixed cohorts

Milano *et al*. found that 39 breast cancer patients (within a 121 patient cohort of all histologies and ≤5 metastases) enrolled across two prospective studies of curative-intent SBRT (50 Gy/5 fractions), fared significantly better with respect to OS, PFS and LC than the whole mixed-histology cohort (126). No patient experienced Grade 4 or 5 toxicity, and only 1 patient experienced Grade 3 toxicity (nonmalignant pleural and pericardial effusion). Long term results were reported by the same group with median follow-up of 4.5 years for breast cancer patients (68). One-third of breast cancer patients were alive at the last follow-up visit (>4 to 10 years) without widespread metastatic disease. The 2- and 6-year OS rates were 74% and 47% respectively. The 2- and 6-year LC rate was 87%. Patients with progression of disease prior to SBRT initiation had a significantly worse 2-year OS rate compared to those who had at least stable disease (55% versus 81%). Fifty-seven percent long-term (>4 years) survivors had one initial metastatic lesion. Unlike other histologies, none of the OMBC patients who died 4 years after SBRT failed locally. None of the 17 bone lesions from breast cancer recurred after SBRT versus 10 of 68 lesions from other organs that recurred (P=0.095).

In a multi-institutional phase I/II trial of SBRT in 47 patients (63 lesions) with any primary tumor (4 with OMBC) and 1–3 liver metastases, patients received 36–60 Gy (118). The overall 2-year LC rate was 92% but, for lesions ≤3 cm 100%. Grade 3 and higher toxicity occurred in only 2% of patients. In another multi-institutional phase I/II trial of SBRT in 38 patients (63 lesions) with any primary tumor (2 with OMBC) and 1–3 lung metastases, patients received 48–60 Gy (119). LC at 1 and 2 years after SBRT was 100% and 96%, respectively.

The incidence of grade 3 toxicity was 8%.

(II) Studies of breast cancer patients only

The longest-term data (30-year results) are reported in a retrospective review by Kobayashi *et al*. of 75 OMBC patients (120). With a preponderance of ER+, HER2-negative, low Ki67 (defined as <14%) patients and 60% with only one involved organ, the estimated median OS was 15 years. OS was significantly improved with single organ involvement, LAT (surgery or radiation), absence of liver metastases, and anthracycline-based chemotherapy. With LATs (n=35), the OS and relapse free rate at 10 years was 82% and 38% and at 20 years, 53% and 38% respectively.

Yoo *et al*. retrospectively reported on 50 OMBC patients (≤5 sites) (8). All patients had bone metastases and seven had pulmonary, hepatic, or LN metastases. Sixty percent had a single metastasis. With only one-third of patients receiving ≥50 Gy_{10} and inconsistent coverage of the entire lesion, the 2-year OS rate for all patients and solitary bone metastasis group were 85% and 97%, respectively. The 3-year LC rate was 70%. The presence of ER+ disease and solitary bone metastasis were independent favorable prognostic factors for survival.

Scorsetti *et al*. reported on an observational study of 33 OMBC patients with either lung (30%) or liver (70%) metastases treated with SBRT (121). Other metastatic sites stable or responding after chemotherapy were allowed and were not subjected to SBRT. Almost 70% were ER+. More than 90% of patients received systemic therapies for metastatic disease before and all of them after SBRT such that this was essentially a study of oligoprogressive or oligopersistent disease. The SBRT dose was higher than in previous studies at 56–75 Gy in 3 fractions and 48–60 Gy in 3–4 fractions, for liver and lung lesions respectively. Only two patients developed progressive disease within the treated target (both in liver). In this study, LC was excellent (1- and 2-year LC rates 98% and 90% respectively) compared to other studies of LATs for visceral lesions. This can be partially explained by the higher deposited dose to the target. There were no G3-4 toxicities. On univariate analysis, DFI >12 months, ER+ disease and medical therapies after SBRT showed a significant impact on OS.

Numerous retrospective and prospective studies have demonstrated the feasibility of SBRT for liver metastases with LC rates ranging between 70–100% at 1 year and 60–90% at 2 years (114,127-129). However, in these studies a wide range of doses and fractionations were used for SBRT delivery in very heterogeneous patient populations with different histologies and primary tumor sites. Onal *et al*.

Table 1 Summary of radiation therapy trials including OMBC patients

Author/year	Disease	Design	Definition	Patients/n	Intervention	LC	PFS	OS	Notes
Milano 2012 (68)	Mixed	Prospective, Single Arm	≤5 lesions in 1–3 organs	121 (39 OMBC)	SBRT 50 Gy/10 fx	Breast: 2 yr 87%; 6 yr 87%	Breast Freedom from distant metastases 2 yr 52%; 6 yr 36%	Breast: 2 yr 74%; 6 yr 47%	Dose finding trial
Salama 2012 (112)	Mixed	Prospective, Single Arm	≤5 lesions	61 (11.3% OMBC)	SBRT 24–60 Gy/ 4 fx		1 yr 33.3%; 2 yr 22%	1 yr 81.5% 2 yr 56.7%	
Andratschke 2018 (113)	Mixed	Meta-analysis	≤4 Liver lesions	474 (13% OMBC)	SBRT	1 yr 76%, (for breast 91%); 3 yr 56%		1 yr 70%; 3 yr 29%	80% have 1 lesion
Goodman 2016 (114)	Mixed	Retrospective	≤3 liver lesions	81 (7.4% OMBC)	SBRT	4 yr 91%		4 yr 28%	
Bhattacharya 2015 (115)	Mixed	Retrospective	≤3 lesions	76 (18% OMBC)	SBRT 24–45 Gy/ 3–5 fx	89% (breast cohort had no local failures)	2 yr 26.2%	2 yr 63.2%	42% lymph node, 29% bone and spine
Fumagalli 2012 (116)	Mixed	Retrospective	≤5 liver or lung lesions	90 (9% OMBC)	SBRT 27–60 Gy/3 fx (median 45 Gy/3 fx)	1 yr 84.5%; 2 yr 66.1%	Median disease-free survival 6.7 mo	OS 2 yr 70%	
Mahadevan 2018 (117)	Mixed	Retrospective	Liver lesions (max # not defined)	427 (10% OMBC)	SBRT median dose 45 Gy [12–60]/3 fx	Median duration of LC 51 mo		Median OS Breast 21 mo	
Rusthoven (118)	Mixed	Prospective, multi-institutional Phase I/II	≤3 liver lesions (<6 cm)	47 (9% OMBC)	Phase I: SBRT 36–60 Gy/3 fx Phase II: SBRT 60 Gy/ 3 fx	Actuarial: 1 yr 95%; 2 yr 92%	Median PFS 6.1 mo	Median OS 20.5 mo	
Rusthoven (119)	Mixed	Prospective, multi-institutional Phase I/II	≤3 lung lesions (<7 cm)	38 (5% OMBC)	Phase I: SBRT 48–60 Gy/3 fx Phase II: SBRT 60 Gy/ 3 fx	1 yr 100%; 2 yr 96%	Median PFS 8.4 mo	Median OS 19 mo	
Kobayashi 2012 (120)	Breast	Retrospective	≤5 lesions per organ (except ≤10 in lung or bones) (1-2 organs, ≤5 cm lesion size)	75	Surgery or radiation in 35 patients	5 yr 45%; 10 yr 27.4%; 15 yr 27.4%; 20 yr 27.4%	5 yr 56.8%; 10 yr 32.8%; 15 yr 29.1%; 20 yr 29.1% Median PFS 68.5 mo	5 yr 79.2%; 10 yr 59.2%; 15 yr 51.2%; 20 yr 34.1% Median OS 185 mo	

Table 1 (*continued*)

Table 1 (*continued*)

Author/year	Disease	Design	Definition	Patients/n	Intervention	LC	PFS	OS	Notes
Yoo 2015 (8)	Breast	Retrospective	≤5 sites	50 OMBC	RT 20–60 Gy (entire target not always covered)	3 yr 70%; 5 yr 66%	Distant PFS 3 yr 37%	2 yr 85% (96% for solitary bone lesion); 5 yr 49%	60% had single lesion, 43/50 only had bone metastases, 2/3 <50 Gy_{10}
Scorsetti 2016 (121)	Breast	Observational	≤4 liver or lung lesions (<5 cm per lesion)	33	SBRT 48/4–60/3 for lung. 56.25–75 Gy/ 3 fx for liver	1 yr 98%; 2 yr 90%	1 yr 48%; 2 yr 27% Median PFS 11 mo	1 yr 93% 2 yr 66% Median OS 48 mon	70% liver, 30% lung, 94% ≤2 lesions
Onal 2018 (122)	Breast	Retrospective	≤5 liver lesions	22	SBRT 54 Gy/3 fx	1 yr 100%; 2 yr 88%	1 yr 38%; 2 yr 8%	1 yr 85%; 2 yr 57%	
Milano 2009 (123)	Breast	Prospective	≤5 lesions	40	SBRT	4 yr 89%	2 yr 44%; 4 yr 38% Median PFS 23 mo Distant control: 2 yr 50%; 4 yr 43%	2 yr 76%; 4 yr 59%	35% liver, 30% lung, 28% bone, 23% thoracic lymph nodes, 70% ≤2 lesions
Trovo 2018 (124)	Breast	Prospective, Single Arm, Phase II	≤5 lesions	54	SBRT 30–45 Gy or IMRT 60 Gy	2 yr 97%	2 yr 53%	2 yr 95%	70% bone, 25% lymph nodes
David 2020 (125)	Breast	Prospective, Single Arm	≤3 bone lesions	15	SBRT 20 Gy/1 fraction	Local PFS 2 yr 100%	Distant PFS 2 yr 67%		73% single lesion, 26% sternum

LC, local control; PFS, progression free survival; OS, overall survival; OMBC, oligometastatic breast cancer; SBRT, stereotactic body radiation therapy.

Table 2 Randomized phase II trials in oligometastatic disease

Trial name/author	Histology	Eligibility	Intervention	Benefit
SABR-COMET, Palma (109,130)	Multiple including breast	≤5 solid tumor metastases	SBRT	Median OS: 28 versus 41 months (P=0.09) 5-year OS: 42.3% versus 17.7% (P=0.006). Median PFS 11.6 *vs.* 5.4 months and PFS at 5 years was 17.3% *vs.* 0% (P=0.001)
Gomez (131)	NSCLC	≤3 NSCLC metastases without progression after 3 months' systemic therapy	RT or surgery	Median OS: 17.0 versus 41.2 months (P=0.017)
				Median PFS: 14.2 versus 23.1 months (P=0.022)
Iyengar (132)	NSCLC	≤5 NSCLC metastases with stable disease after induction chemotherapy	SBRT	Median PFS: 3.5 versus 9.7 months (P=0.01)
STOMP, Ost (133)	Prostate	≤3 asymptomatic, extracranial prostate metastases	RT or surgery	ADT-free survival: 13 versus 21 months (P=0.11)
Oriole, Phillips (134)	Prostate	≤3 castrate-sensitive prostate metastases	SBRT	Median PFS: 5.8 months versus not reached (P=0.002)
EORTC 40004, Ruers (135)	Colorectal	≤10 unresectable colorectal liver metastases, no extrahepatic disease	RFA liver	Hazard ratio for OS: 0.58 (P=0.01)

NSCLC, non-small lung cell cancer; PFS, progression free survival; OS, overall survival; SBRT, stereotactic body radiation therapy; RT, radiation therapy; RFA, radiofrequency ablation; ADT, androgen deprivation therapy.

recently reported on a retrospective review of 22 OMBC patients with 29 liver sites treated with SBRT to a dose of 54 Gy in 3 fractions (122). One- and two-year OS rates were 85% and 57%, PFS rates were 38% and 8%, and LC rates were 100% and 88%, respectively. No significant prognostic factors were found. There was no grade 4/5 toxicity.

Milano *et al.* reported on a prospective study of 40 breast cancer patients (85 lesions) treated with curative intent SBRT (123). The most common site of metastasis was liver [33] followed by lung [17], bones [17], thoracic LN [16] and pelvic or abdominal LN [2]. Eight patients had bone-only disease and 63% were ER+. Over 80% of patients had only one organ and a maximum of 3 lesions involved. ST was administered prior and after SBRT in 36 and 32 cases, respectively. Two- and four-year OS were 76% and 59%, respectively. The 4-year ultimate PFS (incorporating salvage therapy for local failure) was 43%, and tumor LC 89%. No lesions failed locally after 18 months. Patients with bone metastases (n=11) experienced an improved PFS (P=0.037). All 8 patients with bone-only metastases remained alive, and 7 of 8 are with no evidence of disease recurrence at 22–89 months (median 50).

Trovo *et al.* reported on a multicenter phase II study for 54 OMBC patients {92 lesions including bone [60], LN [23], liver [5] and lungs [4]}. They showed that treatment with SBRT (30–45 Gy/3 fractions) or intensity-modulated radiation therapy (60 Gy/25 fractions) resulted in favorable

outcomes (2-year PFS 53%, LC 97%, OS 95%) without any acute grade ≥3 toxicity (124).

A recent prospective single institution study by David *et al.* reported on 15 patients (73% luminal) with ≤3 bone only oligometastases treated with SBRT (20 Gy/1 fraction) (125). The treatment was safe and feasible with 2-year LC of 100% and 2-year PFS 65%. Of 19 treated metastatic sites, five were sternal metastases that were all safely treated. SBRT provides a significantly less invasive alternative to surgical approach in selected patients.

Together, the above findings indicate that the most favorable group for use of LATs in OMBC would be patients with solitary bone metastasis and ER+ disease. Despite good LC for visceral metastases, survival outcomes remain inferior when compared to bone-only disease. Other favorable factors include long DFI and receipt of ST.

(III) Randomized studies

After decades of hypothesis-generating retrospective reports, the value of integrating SBRT into the treatment pathway for OMD was investigated in six randomized phase 2 studies with improvement in either PFS and/or OS (see *Table 2*) (130-135).

One of the larger studies (SABR-COMET) (130) of 99 patients (≤5 lesions in ≤3 per organs) included 18 OMBC patients with controlled primary malignancy. This study showed, for the whole trial population, an OS benefit with SBRT in addition to standard of care (SOC) [41 months in SBRT arm versus 28 months for SOC alone (HR 0.57,

95% CI, 0.3–1.1, P=0.090), noting a prespecified two-sided alpha of 0.20 as part of a phase II screening trial], doubling of PFS to 12 months from 6 months (HR 0.47, 95% CI, 0.3–0.76, P=0.0012) and LC of 75% versus 49% in SBRT versus control arm respectively. However, there was an absolute increase of 20% in the rate of adverse events of ≥ grade 2 in the SBRT arm, with treatment-related deaths occurring in three (from pulmonary abscess, subdural hemorrhage and pneumonitis) of 66 patients after SBRT, compared with none in the control group. At a glance the first two treatment related deaths would not be typically expected secondary to SBRT, whilst the last case appears to be attributable to SBRT (136). About half of the lesions were in the lung, one-third in bone and 75% of patients had ≤2 sites. With extended follow-up, the impact of SBRT on OS was larger in magnitude than in the initial analysis and durable over time (SBRT versus control arm: median survival 50 versus 28 months, OS at 5 years was 42.3% versus 17.7%, median PFS 11.6 versus 5.4 months and PFS at 5 years was 17.3% versus 0%). A comparatively lower magnitude of PFS benefit from SBRT in the setting of longer OS benefit and significant rates of salvage SABR (9 versus 1 patient) might indicate the presence of undetected micrometastatic disease at presentation. With close surveillance and salvage SBRT at progression, it is apparent that post-progression treatment is influencing OS benefit. There were no new safety signals, and SBRT had no detrimental impact on QoL (109).

Other LAT modalities
In unresectable or high-risk surgical liver metastases patients, alternatives to surgery and radiation include RFA and TACE (137-139). Both appear to have low adverse event rates. There are no trials comparing the two modalities, though there is some evidence that the combination appears to be safe and superior to RFA alone (140).

RFA offers effective LC especially for solitary lesions <3 cm in diameter and in those for which a 10-mm margin of ablation could be achieved (141,142). A study comparing laparoscopic liver RFA in MBC patients (who either had no or incomplete response to ST) with patients treated with ST alone reported 47 months OS in the RFA group and 9 months in the ST only group (P=0.0001) (143). A meta-analysis of 14 studies evaluated the efficacy of RFA compared to hepatic resection in MBC patients and found the hepatic resection to be more efficacious (5-year OS combined OR 0.38, P<0.001) although RFA gives rise to fewer postoperative complications and shorter hospital stays (144). The mortality and morbidity with RFA ranges from 0.3% to 0.8% and 2% to 10% respectively (141).

Data suggest that TACE may result in tumor shrinkage and facilitate curative intent resection in patients (145). A retrospective review of MBC patients with liver-only metastases compared combined TACE and ST to ST alone and found 3-year OS of 47.6% in the combined treatment group versus 7.4% in the ST alone group (P=0.027) (146).

Additional low-toxicity local procedures include cryosurgery, laser-induced interstitial thermotherapy, microwave ablation, high-intensity focused ultrasound (HIFU), or tumor embolization with isotope-loaded microspheres (147,148).

Management of intracranial metastases
The optimal treatment of brain metastases remains controversial. Surgery or stereotactic radiosurgery (SRS), possibly integrated with whole brain radiation therapy (WBRT) are available options. The intrinsic breast cancer subtype (basal, luminal A/B, HER2-positive) is a key determinant of prognosis (149,150). Historically, breast cancer is not well represented in published phase III randomized studies of SRS (7–12% of the study populations) (151). Indeed, there are few data specifically addressing different breast cancer subtypes despite the fact that management of extracranial disease differs widely based on subtypes. Future studies specifically addressing treatment outcomes for well-defined patient groups and different tumor subtypes are needed. The number of brain metastases is also an important prognostic factor for survival as well as influencing treatment selection (152).

Broadly speaking, SRS is now the primary treatment for patients with either limited or multiple brain metastases, with potential synergistic effects when combined with certain immunotherapies or targeted therapies (153-155). Fractionated SRS (2–5 fractions) can be considered for patients with large metastases (>2 cm in diameter), recurrent lesions after prior SRS, postoperative cavities or metastases located near sensitive structures (156,157).

Surgery improves the survival outcomes of patients with a single brain-metastatic lesion, a good KPS and a limited number of extracranial metastases (158,159). Postoperative SRS is an alternative to WBRT for patients who undergo resection of brain metastases, with a reduced risk of neurocognitive decline. However, SRS is associated with an increased risk of intracranial failure compared to WBRT, albeit without a corresponding decrement in OS (160). With new systemic therapies showing promising CNS activity they could act as a "whole brain irradiation"

surrogate to control brain micrometastatic disease leaving SRS to control macroscopic foci (161-164). Recent data favors preoperative SRS versus postoperative SRS due to lower risks of radiation necrosis and leptomeningeal disease (165-167).

Ongoing studies and future directions

Studies of OMD are limited by statistical bias and tumor and patient heterogeneity. There are few high-quality published data regarding identification and treatment of OMBC. However increased awareness of OMBC has resulted in several active prospective phase II/III RCTs (see *Table 3*).

Multiple trials are evaluating the use of SBRT and/or traditional surgery in addition to SOC ST in the first line setting for newly diagnosed OMBC [e.g., CLEAR NCT03750396 (168); STEREO-SEIN NCT02089100 (169); NRG BR-002 NCT02364557 (170); NCT02581670 (171), PROMISE-005 NCT03808337 (179)]. A novel pilot phase I study in Australia, evaluating the role of SBRT followed by 6 months of anti-PD1 therapy with pembrolizumab, with a goal of showing both safety and enhanced immune activation, has been recently completed [BOSTON-II, NCT02303366 (172)]. This strategy is of particular interest, given its recent success in lung cancer where a phase II single arm study showed a 13-month PFS benefit compared to historical controls in oligometastatic non-small cell lung cancer (NSCLC) (180). AZTEC (NCT03464942) (173) is evaluating the role of SBRT followed by atezolizumab in TN breast cancer. SABR-COMET-3 (NCT03862911) (175) and SABR-COMET-10 (NCT03721341) (176) are assessing the impact of SBRT on OS in patients with 1–3 and 4–10 metastases, respectively, and accruing patients with a controlled primary tumor of any solid tumor histology including breast. The modification of the number of metastases compared with SABR-COMET is due to the fact that >90% of patients enrolled on it had ≤3 lesions. The expansion of up to 10 metastases in SABR-COMET-10 will allow exploration of the clinical benefits of LAT in patients with more widespread disease. The CORE trial (NCT02759783) (177) is a phase II trial of SBRT with a controlled primary tumor (breast, NSCLC or prostate) and 1–3 metastatic lesions. Not only are these trials prospective and many of them randomized, they also comprise patient populations exposed to modern, guideline-based systemic therapies e.g., endocrine-CDK4/6 inhibitor or mTOR inhibitors.

Currently, a concern with the aforementioned research

studies is that they effectively preselect patients for enrollment based upon having an existing oligometastatic presentation. A proactive imaging protocol such as BCMetPats study (NCT027069640) (181) can evaluate the usefulness of early detection of oligometastases by whole body PET-CT, CT and brain MRI in breast cancer patients with high-risk (>30%) for developing metastatic disease. By documenting the patterns of early metastatic spread of breast cancer, it can potentially provide insight to determine optimal future surveillance imaging protocols with respect to the time to progression, rate of tumor growth and affected organs.

To facilitate comparison of trial results and uniformity in future trial designs, it would be prudent to adopt the consensus definition and the appropriate scenario of OMBC as well as the corresponding endpoint. Two ongoing challenges exist (I) determining which patients truly have OMD and (II) ascertaining who is most likely to experience a meaningful response to LAT. To answer the former, advanced and consistent imaging and circulating biomarkers, such as microRNA and ctDNA may improve our ability to characterize disease burden and behavior. To address the latter requires a more complete understanding of response to radiotherapy, metastatic process and the immune system. A deeper understanding of this process and subsequent development of predictive biomarkers may be obtained through sequencing of biopsy or liquid biopsy specimens to explore relationships and lineages of specific metastases in these patients or through advances in analysis of circulating readouts, such as CTCs, ctDNA, and circulating T cell repertoires. With many of the ongoing trials planning to obtain such exploratory biological correlates, careful analysis of these will be valuable in increasing our understanding of metastatic biology as well as which patients obtain clinical benefit from LAT.

Conclusions

Given ongoing improvements in ST, up to a fifth of MBC patients are now presenting with OMBC. Imaging techniques for identifying OMBC are improving and classification of OMBC scenarios as per ASTRO-ESTRO consensus will help in evaluating outcomes of LAT at different points in the disease's evolution. RCT data from a mixed patient cohort hints at likely OS benefits of SBRT in the OMBC setting. Ongoing prospective and randomized studies will help to define subgroups most likely to gain from ablative treatment of OMBC but are challenging to

Table 3 Summary of ongoing/recently completed clinical trials of SBRT in OMBC patients

Principal Investigator	NCT	Disease	Design	Definition	Target Accrual	Intervention	Outcome
Jeong (168)	NCT03750396	ER-positive/HER2-negative; breast cancer	Single arm, phase II, multicenter	≤2 lesions (size ≤3 cm) in single organ or site	110	CLEAR: local treatment (SBRT/surgery/RFA) in addition to endocrine therapy (CDK4/6 inhibitor or mTOR inhibitors)	Primary: PFS; Secondary: OS
Bourgier (169)	NCT02089100	De novo oligometastatic breast cancer	Randomized, phase III, multicenter	≤5 lesions (each ≤10 cm or ≤500 mL, ≤7 cm for liver)	280	STEREO-SEIN: SBRT + systemic treatment vs. systemic treatment alone	Primary: PFS; Secondary: LF, OS
Chmura (170) NCT02364557, NRG BR-002 Phase II accrual met in 2019		Breast	Randomized phase II/III	≤4 lesions (≤5 cm each)	402	Standard of care vs. standard of care + SBRT and/or surgery	Primary: PFS, OS; Secondary: presence of CTC (baseline, after treatment); levels of ctDNA; incidence AE's; appearance of new metastases
De Rose, Comito (171)	NCT02581670	Breast *Lung/liver metastases	Non-randomized phase II	≤4 lesions (<5 cm)	58	SBRT to medically inoperable lung and liver lesions	Primary: local control, toxicity Secondary: PFS, OS
Steven, Loi (172)	NCT02303366 (Completed)	Breast	Prospective single arm phase I	≤5 lesions	15	BOSTON-II, SBRT (20 Gy ×1) + MK-3475 (Pembrolizumab) ×8 cycles	Primary: acute and late adverse events; Secondary: immunological effects, efficacy
Steven, Loi (173)	NCT03464942	Breast (triple negative)	Randomized phase II multicenter	≤4 lesions with at least one untreated lesion	52	AZTEC, (20 Gy ×1 vs. 8 Gy ×3), SBRT followed by Atezolizumab ×24 months	Primary: PFS; Secondary: response, safety, OS
Dirix (174)	NCT03486431 (completed)	Mixed	Prospective, phase I	≤3 lesions (<5 cm)	90	Destroy: dose-escalation trial for non-spine bone & lymph node oligometastases; SBRT (5×7 Gy, 3×10 Gy, 1×20 Gy)	Primary: DLT; Secondary: Median PFS; local control rate
Olson (175)	NCT03862911	Mixed	Randomized phase III	≤3 lesions (intracranial included)	297	SABR-COMET 3: standard of care with and without SBRT	Primary: OS; Secondary: toxicity, PFS, QoL, CTC, ctDNA
Palma (176)	NCT03721341	Mixed	Randomized phase III	4–10 lesions (intracranial included)	159	SABR-COMET 10: standard of care with and without SBRT	Primary: OS; Secondary: toxicity, PFS, QoL
Khoo (177)	NCT02759783	Breast, prostate, NSCLC	Randomized phase II multicenter	≤3 lesions in ≤2 organs	245	CORE: standard of care +/− SBRT to extracranial metastases	Primary: PFS; Secondary: OS, local control, toxicity
Tsai (178)	NCT03808662	Triple negative breast cancer, non-small cell lung cancer	Randomized phase II	≤5 progressing lesions	160	PROMISE-004: Precision Radiation for OligoMetastatIc and MetaStatic DiseasE (PROMISE)-004: Consolidative Use of Radiotherapy to Block (CURB) oligoprogression	Primary: PFS; Secondary: OS
Yang (179)	NCT03808337	Triple negative breast cancer, non-small cell lung cancer	Randomized phase II	≤5 lesions	142	PROMISE-005: standard of care +/− SBRT in breast and lung cancer	Primary: PFS; Secondary: OS

ER, estrogen receptor; SBRT, stereotactic body radiotherapy; RFA, radiofrequency ablation; PFS, progression-free survival; OS, overall survival; LF, CTC, circulating tumor cell; QoL, quality of life.

fund and accrue and take time to deliver outcome data.

In the meantime, SBRT has been widely adopted in radiation oncology. Recognizing the need to address gaps in current knowledge before increasing clinical experience and expert opinion alter the balance of equipoise, Oligocare, a prospective registry, for collecting data on baseline factors and outcomes in patients undergoing SBRT for OMD has been established. Collection of detailed prospective data in large patient numbers provides another means of identifying factors predictive of those in whom SBRT will be associated with the most durable benefits. Ongoing efforts to understand the biological mechanisms underpinning metastatic potential will also help us refine our definitions of OMBC, determine how LATs interact with the biology of OMBC, and improve patient selection for ablative therapies including SBRT.

Acknowledgments

Footnote

Provenance and Peer Review: This article was commissioned by the Guest Editors (William Small Jr. and Parul Barry) for the series "Advancements and Opportunities for Breast Irradiation" published in *Annals of Breast Surgery*. The article has undergone external peer review.

Conflicts of Interest: Both authors have completed the ICMJE uniform disclosure form (available at https://abs.amegroups. com/article/view/10.21037/abs-20-145/coif). The series "Advancements and Opportunities for Breast Irradiation" was commissioned by the editorial office without any funding or sponsorship. The authors have no other conflicts of interest to declare.

Ethical Statement: The authors are accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0/.

References

1. Valastyan S, Weinberg RA. Tumor metastasis: molecular insights and evolving paradigms. Cell 2011;147:275-92.

2. Hellman S. Karnofsky Memorial Lecture. Natural history of small breast cancers. J Clin Oncol 1994;12:2229-34.

3. Hellman S, Weichselbaum RR. Oligometastases. J Clin Oncol 1995;13:8-10.

4. Lin D. Commentary on "The evolutionary history of lethal metastatic prostate cancer." Gundem G, Van Loo P, Kremeyer B, Alexandrov LB, Tubio JM, Papaemmanuil E, Brewer DS, Kallio HM, Högnäs G, Annala M, Kivinummi K, Goody V, Latimer C, O'Meara S, Dawson KJ, Isaacs W, Emmert-Buck MR, Nykter M, Foster C, Kote-Jarai Z, Easton D, Whitaker HC, ICGC Prostate UK Group, Neal DE, Cooper CS, Eeles RA, Visakorpi T, Campbell PJ, McDermott U, Wedge DC, Bova GS, University of Washington-Urology, Seattle, WA. Nature 2015; 520(7547):353-7. Urol Oncol 2016;34:520-1.

5. Guckenberger M, Lievens Y, Bouma AB, et al. Characterisation and classification of oligometastatic disease: a European Society for Radiotherapy and Oncology and European Organisation for Research and Treatment of Cancer consensus recommendation. Lancet Oncol 2020;21:e18-e28.

6. Cooper C, Booth A, Varley-Campbell J, et al. Defining the process to literature searching in systematic reviews: a literature review of guidance and supporting studies. BMC Med Res Methodol 2018;18:85.

7. Ashworth AB, Senan S, Palma DA, et al. An individual patient data metaanalysis of outcomes and prognostic factors after treatment of oligometastatic non-small-cell lung cancer. Clin Lung Cancer 2014;15:346-55.

8. Yoo GS, Yu JI, Park W, et al. Prognostic factors in breast cancer with extracranial oligometastases and the appropriate role of radiation therapy. Radiat Oncol J 2015;33:301-9.

9. Conde Moreno AJ, Ferrer Albiach C, Muelas Soria R, et al. Oligometastases in prostate cancer: restaging stage IV cancers and new radiotherapy options. Radiat Oncol 2014;9:258.

10. Dingemans AC, Hendriks LEL, Berghmans T, et al. Definition of synchronous oligo-metastatic non-small cell lung cancer - a consensus report. J Thorac Oncol

2019;14:2109-19.

11. Lievens Y, Guckenberger M, Gomez D, et al. Defining oligometastatic disease from a radiation oncology perspective: An ESTRO-ASTRO consensus document. Radiother Oncol 2020;148:157-66.

12. Correa RJ, Salama JK, Milano MT, et al. Stereotactic Body Radiotherapy for Oligometastasis: Opportunities for Biology to Guide Clinical Management. Cancer J 2016;22:247-56.

13. Reyes DK, Pienta KJ. The biology and treatment of oligometastatic cancer. Oncotarget 2015;6:8491-524.

14. Klein CA. Selection and adaptation during metastatic cancer progression. Nature 2013;501:365-72.

15. Vera-Ramirez L, Vodnala SK, Nini R, et al. Autophagy promotes the survival of dormant breast cancer cells and metastatic tumour recurrence. Nat Commun 2018;9:1994.

16. Flynn AB, Schiemann WP. Autophagy in breast cancer metastatic dormancy: Tumor suppressing or tumor promoting functions? J Cancer Metastasis Treat 2019;5:43.

17. Romero MA, Ekmekcigil OB, Bagca BG, et al. Role of autophagy in breast cancer development and progression: opposite sides of the same coin. Breast Cancer Metastasis and Drug Resistance. Springer, 2019:65-73.

18. Peyvandi S, Lan Q, Lorusso G, et al. Chemotherapy-induced immunological breast cancer dormancy: a new function for old drugs? J Cancer Metastasis Treat 2019;5:44.

19. Nik-Zainal S, Van Loo P, Wedge DC, et al. The life history of 21 breast cancers. Cell 2012;149:994-1007.

20. Gerlinger M, Rowan AJ, Horswell S, et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med 2012;366:883-92.

21. Brastianos PK, Carter SL, Santagata S, et al. Genomic Characterization of Brain Metastases Reveals Branched Evolution and Potential Therapeutic Targets. Cancer Discov 2015;5:1164-77.

22. Turajlic S, Xu H, Litchfield K, et al. Tracking cancer evolution reveals constrained routes to metastases: TRACERx renal. Cell 2018;173:581-94. e12.

23. Turajlic S, Swanton C. Metastasis as an evolutionary process. Science 2016;352:169-75.

24. Abbosh C, Birkbak NJ, Wilson GA, et al. Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution. Nature 2017;545:446-51.

25. Haffner MC, Mosbruger T, Esopi DM, et al. Tracking the clonal origin of lethal prostate cancer. J Clin Invest 2013;123:4918-22.

26. Lussier YA, Xing HR, Salama JK, et al. MicroRNA expression characterizes oligometastasis (es). PLoS One 2011;6:e28650.

27. Lussier YA, Khodarev NN, Regan K, et al. Oligo- and polymetastatic progression in lung metastasis (es) patients is associated with specific microRNAs. PLoS One 2012;7:e50141.

28. Uppal A, Wightman SC, Mallon S, et al. 14q32-encoded microRNAs mediate an oligometastatic phenotype. Oncotarget 2015;6:3540-52.

29. Uppal A, Ferguson MK, Posner MC, et al. Towards a molecular basis of oligometastatic disease: potential role of micro-RNAs. Clin Exp Metastasis 2014;31:735-48.

30. Pitroda SP, Chmura SJ, Weichselbaum RR. Integration of radiotherapy and immunotherapy for treatment of oligometastases. Lancet Oncol 2019;20:e434-42.

31. Jain SK, Dorn PL, Chmura SJ, et al. Incidence and implications of oligometastatic breast cancer. American Society of Clinical Oncology; 2012.

32. Pagani O, Senkus E, Wood W, et al. International guidelines for management of metastatic breast cancer: can metastatic breast cancer be cured? J Natl Cancer Inst 2010;102:456-63.

33. Radan L, Ben-Haim S, Bar-Shalom R, et al. The role of FDG-PET/CT in suspected recurrence of breast cancer. Cancer 2006;107:2545-51.

34. Fueger BJ, Weber WA, Quon A, et al. Performance of 2-deoxy-2-[F-18] fluoro-D-glucose positron emission tomography and integrated PET/CT in restaged breast cancer patients. Mol Imaging Biol 2005;7:369-76.

35. Briasoulis E, Karavasilis V, Kostadima L, et al. Metastatic breast carcinoma confined to bone: portrait of a clinical entity. Cancer 2004;101:1524-8.

36. Coleman RE, Smith P, Rubens R. Clinical course and prognostic factors following bone recurrence from breast cancer. Br J Cancer 1998;77:336-40.

37. Ahn SG, Lee HM, Cho SH, et al. Prognostic factors for patients with bone-only metastasis in breast cancer. Yonsei Med J 2013;54:1168-77.

38. Ohta M, Tokuda Y, Suzuki Y, et al. Whole body PET for the evaluation of bony metastases in patients with breast cancer: comparison with 99Tcm-MDP bone scintigraphy. Nucl Med Commun 2001;22:875-9.

39. deSouza NM, Liu Y, Chiti A, et al. Strategies and technical challenges for imaging oligometastatic disease: Recommendations from the European Organisation for Research and Treatment of Cancer imaging group. Eur J Cancer 2018;91:153-63.

40. Xiao W, Zheng S, Liu P, et al. Risk factors and survival

outcomes in patients with breast cancer and lung metastasis: a population-based study. Cancer Med 2018;7:922-30.

41. Melsaether AN, Raad RA, Pujara AC, et al. Comparison of whole-body 18F FDG PET/MR imaging and whole-body 18F FDG PET/CT in terms of lesion detection and radiation dose in patients with breast cancer. Radiology 2016;281:193-202.

42. Heusch P, Nensa F, Schaarschmidt B, et al. Diagnostic accuracy of whole-body PET/MRI and whole-body PET/CT for TNM staging in oncology. Eur J Nucl Med Mol Imaging 2015;42:42-8.

43. Antoch G, Vogt FM, Freudenberg LS, et al. Whole-body dual-modality PET/CT and whole-body MRI for tumor staging in oncology. JAMA 2003;290:3199-206.

44. Zhao HY, Gong Y, Ye FG, et al. Incidence and prognostic factors of patients with synchronous liver metastases upon initial diagnosis of breast cancer: a population-based study. Cancer Manag Res 2018;10:5937-50.

45. Stranzl H, Peintinger F, Ofner P, et al. Regional nodal recurrence in the management of breast cancer patients with one to three positive axillary lymph nodes. Outcome of patients following tangential irradiation without a separate nodal field. Strahlenther Onkol 2004;180:623-8.

46. Pejavar S, Wilson LD, Haffty BG. Regional nodal recurrence in breast cancer patients treated with conservative surgery and radiation therapy (BCS+RT). Int J Radiat Oncol Biol Phys 2006;66:1320-7.

47. Whelan TJ, Olivotto IA, Parulekar WR, et al. Regional Nodal Irradiation in Early-Stage Breast Cancer. N Engl J Med 2015;373:307-16.

48. Matsushita H, Jingu K, Umezawa R, et al. Stereotactic Radiotherapy for Oligometastases in Lymph Nodes-A Review. Technol Cancer Res Treat 2018;17:1533033818803597.

49. Heusner TA, Kuemmel S, Koeninger A, et al. Diagnostic value of diffusion-weighted magnetic resonance imaging (DWI) compared to FDG PET/CT for whole-body breast cancer staging. Eur J Nucl Med Mol Imaging 2010;37:1077-86.

50. Schmidt GP, Baur-Melnyk A, Haug A, et al. Comprehensive imaging of tumor recurrence in breast cancer patients using whole-body MRI at 1.5 and 3 T compared to FDG–PET–CT. Eur J Radiol 2008;65:47-58.

51. Sawicki LM, Grueneisen J, Schaarschmidt BM, et al. Evaluation of 18F-FDG PET/MRI, 18F-FDG PET/CT, MRI, and CT in whole-body staging of recurrent breast cancer. Eur J Radiol 2016;85:459-65.

52. Martin AM, Cagney DN, Catalano PJ, et al. Brain metastases in newly diagnosed breast cancer: a population-based study. JAMA Oncol 2017;3:1069-77.

53. Dawood S, Gonzalez-Angulo AM. Progress in the biological understanding and management of breast cancer-associated central nervous system metastases. Oncologist 2013;18:675-84.

54. Lim E, Lin NU. New insights and emerging therapies for breast cancer brain metastases. Oncology (Williston Park) 2012;26:652-9, 63.

55. Berghoff A, Bago-Horvath Z, De Vries C, et al. Brain metastases free survival differs between breast cancer subtypes. Br J Cancer 2012;106:440-6.

56. Weil RJ, Palmieri DC, Bronder JL, et al. Breast cancer metastasis to the central nervous system. Am J Pathol 2005;167:913-20.

57. Freedman RA, Gelman RS, Anders CK, et al. TBCRC 022: a phase II trial of neratinib and capecitabine for patients with human epidermal growth factor receptor 2–positive breast cancer and brain metastases. J Clin Oncol 2019;37:1081.

58. Kennecke H, Yerushalmi R, Woods R, et al. Metastatic behavior of breast cancer subtypes. J Clin Oncol 2010;28:3271-7.

59. Berghoff AS, Bago-Horvath Z, Ilhan-Mutlu A, et al. Brain-only metastatic breast cancer is a distinct clinical entity characterised by favourable median overall survival time and a high rate of long-term survivors. Br J Cancer 2012;107:1454-8.

60. deSouza NM, Tempany CM. A risk-based approach to identifying oligometastatic disease on imaging. Int J Cancer 2019;144:422-30.

61. Heitmann J, Guckenberger M. Perspectives on oligometastasis: challenges and opportunities. J Thorac Dis 2018;10:113-7.

62. de Jong MC, Mayo SC, Pulitano C, et al. Repeat curative intent liver surgery is safe and effective for recurrent colorectal liver metastasis: results from an international multi-institutional analysis. J Gastrointest Surg 2009;13:2141.

63. Meimarakis G, Rüttinger D, Stemmler J, et al. Prolonged overall survival after pulmonary metastasectomy in patients with breast cancer. Ann Thorac Surg 2013;95:1170-80.

64. McDonald ML, Deschamps C, Ilstrup DM, et al. Pulmonary resection for metastatic breast cancer. Ann Thorac Surg 1994;58:1599-602.

65. Yoshimoto M, Tada K, Nishimura S, et al. Favourable long-term results after surgical removal of lung

metastases of breast cancer. Breast Cancer Res Treat 2008;110:485-91.

66. Chua TC, Saxena A, Liauw W, et al. Hepatic resection for metastatic breast cancer: a systematic review. Eur J Cancer 2011;47:2282-90.

67. Kocher M, Müller R, Staar S, et al. Long-term survival after brain metastases in breast cancer. Strahlenther Onkol 1995;171:290-5.

68. Milano MT, Katz AW, Zhang H, et al. Oligometastases Treated With Stereotactic Body Radiotherapy: Long-Term Follow-Up of Prospective Study. Int J Radiat Oncol Biol Phys 2012;83:878-86.

69. Juric D, Castel P, Griffith M, et al. Convergent loss of PTEN leads to clinical resistance to a PI (3) Kα inhibitor. Nature 2015;518:240-4.

70. Savas P, Teo ZL, Lefevre C, et al. The subclonal architecture of metastatic breast cancer: results from a prospective community-based rapid autopsy program "CASCADE". PLoS Med 2016;13:e1002204.

71. Tosello G, Torloni MR, Mota BS, et al. Breast surgery for metastatic breast cancer. Cochrane Database Syst Rev 2018;3:CD011276.

72. Ruiterkamp J, Voogd AC, Bosscha K, et al. Impact of breast surgery on survival in patients with distant metastases at initial presentation: a systematic review of the literature. Breast Cancer Res Treat 2010;120:9-16.

73. Gnerlich J, Dueker JM, Jeffe DB, et al. Patient and tumor characteristics associated with primary tumor resection in women with stage iv breast cancer: analysis of 1988–2003 SEER data. Breast J 2008;14:538-42.

74. Le Scodan R, Stevens D, Brain E, et al. Breast cancer with synchronous metastases: survival impact of exclusive locoregional radiotherapy. J Clin Oncol 2009;27:1375-81.

75. Cao KI, Lebas N, Gerber S, et al. Phase II randomized study of whole-brain radiation therapy with or without concurrent temozolomide for brain metastases from breast cancer. Ann Oncol 2015;26:89-94.

76. Danna EA, Sinha P, Gilbert M, et al. Surgical removal of primary tumor reverses tumor-induced immunosuppression despite the presence of metastatic disease. Cancer Res 2004;64:2205-11.

77. Morgan SC, Parker CC. Local treatment of metastatic cancer—killing the seed or disturbing the soil? Nat Rev Clin Oncol 2011;8:504-6.

78. Khan SA, Stewart AK, Morrow M. Does aggressive local therapy improve survival in metastatic breast cancer? Surgery 2002;132:620-6.

79. Rapiti E, Verkooijen HM, Vlastos G, et al. Complete excision of primary breast tumor improves survival of patients with metastatic breast cancer at diagnosis. J Clin Oncol 2006;24:2743-9.

80. Harris E, Barry M, Kell MR. Meta-analysis to determine if surgical resection of the primary tumour in the setting of stage IV breast cancer impacts on survival. Ann Surg Oncol 2013;20:2828-34.

81. Vohra NA, Brinkley J, Kachare S, et al. Primary tumor resection in metastatic breast cancer: A propensity-matched analysis, 1988-2011 SEER data base. Breast J 2018;24:549-54.

82. Barinoff J, Schmidt M, Schneeweiss A, et al. Primary metastatic breast cancer in the era of targeted therapy– Prognostic impact and the role of breast tumour surgery. Eur J Cancer 2017;83:116-24.

83. King TA, Lyman JP, Gonen M, et al. A prospective analysis of surgery and survival in stage IV breast cancer (TBCRC 013). J Clin Oncol 2016;34:2359-65.

84. Badwe R, Hawaldar R, Nair N, et al. Locoregional treatment versus no treatment of the primary tumour in metastatic breast cancer: an open-label randomised controlled trial. Lancet Oncol 2015;16:1380-8.

85. Soran A, Ozmen V, Ozbas S, et al. Randomized Trial Comparing Resection of Primary Tumor with No Surgery in Stage IV Breast Cancer at Presentation: Protocol MF07-01. Ann Surg Oncol 2018;25:3141-9.

86. Khan SA, Zhao F, Solin LJ, et al. A randomized phase III trial of systemic therapy plus early local therapy versus systemic therapy alone in women with de novo stage IV breast cancer: A trial of the ECOG-ACRIN Research Group (E2108). J Clin Oncol 2020;38:LBA2.

87. Parker CC, James ND, Brawley CD, et al. Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial. Lancet (London, England) 2018;392:2353-66.

88. Weichselbaum RR, Hellman S. Oligometastases revisited. Nat Rev Clin Oncol 2011;8:378-82.

89. Donovan E, Dhesy-Thind S, Mukherjee S, et al. Attitudes and beliefs toward the use of stereotactic body radiotherapy in oligometastatic breast cancer: A commentary on a survey of Canadian Medical Oncologists. Breast J 2019;25:1222-4.

90. Wegener B, Schlemmer M, Stemmler J, et al. Analysis of orthopedic surgery of bone metastases in breast cancer patients. BMC Musculoskelet Disord 2012;13:232.

91. Noguchi S, Miyauchi K, Nishizawa Y, et al. Results of surgical treatment for sternal metastasis of breast cancer. Cancer 1988;62:1397-401.

92. Noble J, Sirohi B, Ashley S, et al. Sternal/para-sternal resection for parasternal local recurrence in breast cancer. Breast 2010;19:350-4.

93. Fairhurst K, Leopardi L, Satyadas T, et al. The safety and effectiveness of liver resection for breast cancer liver metastases: A systematic review. Breast 2016;30:175-84.

94. Howlader M, Heaton N, Rela M. Resection of liver metastases from breast cancer: towards a management guideline. Int J Surg 2011;9:285-91.

95. Yoo TG, Cranshaw I, Broom R, et al. Systematic review of early and long-term outcome of liver resection for metastatic breast cancer: Is there a survival benefit? Breast 2017;32:162-72.

96. Mariani P, Servois V, De Rycke Y, et al. Liver metastases from breast cancer: Surgical resection or not? A case-matched control study in highly selected patients. Eur J Surg Oncol 2013;39:1377-83.

97. van Walsum GA, de Ridder JA, Verhoef C, et al. Resection of liver metastases in patients with breast cancer: survival and prognostic factors. Eur J Surg Oncol 2012;38:910-7.

98. Abbott DE, Brouquet A, Mittendorf EA, et al. Resection of liver metastases from breast cancer: estrogen receptor status and response to chemotherapy before metastasectomy define outcome. Surgery 2012;151:710-6.

99. Nichols FC. Pulmonary metastasectomy. Thorac Surg Clin 2012;22:91-9, vii.

100. Song Z, Ye T, Ma L, et al. Surgical outcomes of isolated malignant pulmonary nodules in patients with a history of breast cancer. Ann Surg Oncol 2017;24:3748-53.

101. Simpson R, Kennedy C, Carmalt H, et al. Pulmonary resection for metastatic breast cancer. Aust N Z J Surg 1997;67:717-9.

102. Kycler W, Laski P. Surgical approach to pulmonary metastases from breast cancer. Breast J 2012;18:52-7.

103. Chen F, Fujinaga T, Sato K, et al. Clinical features of surgical resection for pulmonary metastasis from breast cancer. Eur J Surg Oncol 2009;35:393-7.

104. Welter S, Jacobs J, Krbek T, et al. Pulmonary metastases of breast cancer. When is resection indicated? Eur J Cardiothorac Surg 2008;34:1228-34.

105. Staren ED, Salerno C, Rongione A, et al. Pulmonary resection for metastatic breast cancer. Arch Surg 1992;127:1282-4.

106. Fan J, Chen D, Du H, et al. Prognostic factors for resection of isolated pulmonary metastases in breast cancer patients: a systematic review and meta-analysis. J Thorac Dis 2015;7:1441-51.

107. Pompili C, Absolom K, Franks K, et al. Are quality of life outcomes comparable following stereotactic radiotherapy and minimally invasive surgery for stage I lung cancer patients? J Thorac Dis 2018;10:7055-63.

108. Olson R, Senan S, Harrow S, et al. Quality of Life Outcomes After Stereotactic Ablative Radiation Therapy (SABR) Versus Standard of Care Treatments in the Oligometastatic Setting: A Secondary Analysis of the SABR-COMET Randomized Trial. Int J Radiat Oncol Biol Phys 2019;105:943-7.

109. Palma DA, Olson R, Harrow S, et al. Stereotactic Ablative Radiotherapy for the Comprehensive Treatment of Oligometastatic Cancers: Long-Term Results of the SABR-COMET Phase II Randomized Trial. J Clin Oncol 2020;38:2830-8.

110. Potters L, Kavanagh B, Galvin JM, et al. American Society for Therapeutic Radiology and Oncology (ASTRO) and American College of Radiology (ACR) practice guideline for the performance of stereotactic body radiation therapy. Int J Radiat Oncol Biol Phys 2010;76:326-32.

111. Chan M, Palma D, Barry A, et al. Practical Considerations for the Implementation of a Stereotactic Body Radiation Therapy Program for Oligo-Metastases. Adv Radiat Oncol 2020;6:100499.

112. Salama JK, Hasselle MD, Chmura SJ, et al. Stereotactic body radiotherapy for multisite extracranial oligometastases. Cancer 2012;118:2962-70.

113. Andratschke N, Alheid H, Allgauer M, et al. The SBRT database initiative of the German Society for Radiation Oncology (DEGRO): patterns of care and outcome analysis of stereotactic body radiotherapy (SBRT) for liver oligometastases in 474 patients with 623 metastases. BMC Cancer 2018;18:283.

114. Goodman BD, Mannina EM, Althouse SK, et al. Long-term safety and efficacy of stereotactic body radiation therapy for hepatic oligometastases. Pract Radiat Oncol 2016;6:86-95.

115. Bhattacharya IS, Woolf DK, Hughes RJ, et al. Stereotactic body radiotherapy (SBRT) in the management of extracranial oligometastatic (OM) disease. Br J Radiol 2015;88:20140712.

116. Fumagalli I, Bibault JE, Dewas S, et al. A single-institution study of stereotactic body radiotherapy for patients with unresectable visceral pulmonary or hepatic oligometastases. Radiat Oncol 2012;7:164.

117. Mahadevan A, Blanck O, Lanciano R, et al. Stereotactic Body Radiotherapy (SBRT) for liver metastasis – clinical outcomes from the international multi-institutional RSSearch® Patient Registry. Radiat Oncol 2018;13:26.

118. Rusthoven KE, Kavanagh BD, Cardenes H, et al. Multi-institutional phase I/II trial of stereotactic body radiation therapy for liver metastases. J Clin Oncol 2009;27:1572-8.

119. Rusthoven KE, Kavanagh BD, Burri SH, et al. Multi-institutional phase I/II trial of stereotactic body radiation therapy for lung metastases. J Clin Oncol 2009;27:1579-84.

120. Kobayashi T, Ichiba T, Sakuyama T, et al. Possible clinical cure of metastatic breast cancer: lessons from our 30-year experience with oligometastatic breast cancer patients and literature review. Breast Cancer 2012;19:218-37.

121. Scorsetti M, Franceschini D, De Rose F, et al. Stereotactic body radiation therapy: A promising chance for oligometastatic breast cancer. Breast 2016;26:11-7.

122. Onal C, Guler OC, Yildirim BA. Treatment outcomes of breast cancer liver metastasis treated with stereotactic body radiotherapy. Breast 2018;42:150-6.

123. Milano MT, Zhang H, Metcalfe SK, et al. Oligometastatic breast cancer treated with curative-intent stereotactic body radiation therapy. Breast Cancer Res Treat 2009;115:601-8.

124. Trovo M, Furlan C, Polesel J, et al. Radical radiation therapy for oligometastatic breast cancer: Results of a prospective phase II trial. Radiother Oncol 2018;126:177-80.

125. David S, Tan J, Savas P, et al. Stereotactic ablative body radiotherapy (SABR) for bone only oligometastatic breast cancer: A prospective clinical trial. Breast 2020;49:55-62.

126. Milano MT, Katz AW, Muhs AG, et al. A prospective pilot study of curative-intent stereotactic body radiation therapy in patients with 5 or fewer oligometastatic lesions. Cancer 2008;112:650-8.

127. Scorsetti M, Arcangeli S, Tozzi A, et al. Is stereotactic body radiation therapy an attractive option for unresectable liver metastases? A preliminary report from a phase 2 trial. Int J Radiat Oncol Biol Phys 2013;86:336-42.

128. Lee MT, Kim JJ, Dinniwell R, et al. Phase I study of individualized stereotactic body radiotherapy of liver metastases. J Clin Oncol 2009;27:1585-91.

129. Goodman KA, Kavanagh BD, editors. Stereotactic body radiotherapy for liver metastases. Seminars in Radiation Oncology; 2017: Elsevier.

130. Palma DA, Olson R, Harrow S, et al. Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial. Lancet 2019;393:2051-8.

131. Gomez DR, Tang C, Zhang J, et al. Local Consolidative Therapy Vs. Maintenance Therapy or Observation for Patients With Oligometastatic Non-Small-Cell Lung Cancer: Long-Term Results of a Multi-Institutional, Phase II, Randomized Study. J Clin Oncol 2019;37:1558-65.

132. Iyengar P, Wardak Z, Gerber DE, et al. Consolidative Radiotherapy for Limited Metastatic Non-Small-Cell Lung Cancer: A Phase 2 Randomized Clinical Trial. JAMA Oncol 2018;4:e173501.

133. Ost P, Reynders D, Decaestecker K, et al. Surveillance or Metastasis-Directed Therapy for Oligometastatic Prostate Cancer Recurrence: A Prospective, Randomized, Multicenter Phase II Trial. J Clin Oncol 2018;36:446-53.

134. Phillips R, Shi WY, Deek M, et al. Outcomes of Observation vs Stereotactic Ablative Radiation for Oligometastatic Prostate Cancer: The ORIOLE Phase 2 Randomized Clinical Trial. JAMA Oncol 2020;6:650-9.

135. Ruers T, Van Coevorden F, Punt CJ, et al. Local treatment of unresectable colorectal liver metastases: results of a randomized phase II trial. J Natl Cancer Inst 2017;109:djx015.

136. Sogono P, Ball DL, Siva S. SABR-COMET: a new paradigm of care lights up the twilight of metastatic disease. Ann Transl Med 2019;7:615.

137. Martin RC, Robbins K, Fagés JF, et al. Optimal outcomes for liver-dominant metastatic breast cancer with transarterial chemoembolization with drug-eluting beads loaded with doxorubicin. Breast Cancer Res Treat 2012;132:753-63.

138. Bai XM, Yang W, Zhang ZY, et al. Long-term outcomes and prognostic analysis of percutaneous radiofrequency ablation in liver metastasis from breast cancer. Int J Hyperthermia 2019;35:183-93.

139. Seidensticker M, Garlipp B, Scholz S, et al. Locally ablative treatment of breast cancer liver metastases: identification of factors influencing survival (the Mammary Cancer Microtherapy and Interventional Approaches (MAMMA MIA) study). BMC Cancer 2015;15:517.

140. Wang H, Liu B, Long H, et al. Clinical study of radiofrequency ablation combined with TACE in the treatment of breast cancer with liver metastasis. Oncol Lett 2017;14:2699-702.

141. Shah DR, Green S, Elliot A, et al. Current oncologic applications of radiofrequency ablation therapies. World J Gastrointest Oncol 2013;5:71-80.

142. Shady W, Petre EN, Gonen M, et al. Percutaneous radiofrequency ablation of colorectal cancer liver metastases: factors affecting outcomes—a 10-year experience at a single center. Radiology 2016;278:601-11.

143. Taşçi Y, Aksoy E, Taşkın HE, et al. A comparison of

laparoscopic radiofrequency ablation versus systemic therapy alone in the treatment of breast cancer metastasis to the liver. HPB (Oxford) 2013;15:789-93.

144. Xiao YB, Zhang B, Wu YL. Radiofrequency ablation versus hepatic resection for breast cancer liver metastasis: a systematic review and meta-analysis. Journal of Zhejiang University-SCIENCE B 2018;19:829-43.

145. Camacho LH, Kurzrock R, Cheung A, et al. Pilot study of regional, hepatic intra-arterial paclitaxel in patients with breast carcinoma metastatic to the liver. Cancer 2007;109:2190-6.

146. Duan XF, Dong NN, Zhang T, et al. Treatment outcome of patients with liver-only metastases from breast cancer after mastectomy: a retrospective analysis. J Cancer Res Clin Oncol 2011;137:1363-70.

147. Vogl TJ, Farshid P, Naguib NN, et al. Thermal ablation therapies in patients with breast cancer liver metastases: a review. Eur Radiol 2013;23:797-804.

148. Hoffmann RT, Paprottka P, Jakobs TF, et al. Arterial therapies of non-colorectal cancer metastases to the liver (from chemoembolization to radioembolization). Abdom Imaging 2011;36:671-6.

149. Miller JA, Kotecha R, Ahluwalia MS, et al. Overall survival and the response to radiotherapy among molecular subtypes of breast cancer brain metastases treated with targeted therapies. Cancer 2017;123:2283-93.

150. Sperduto PW, Kased N, Roberge D, et al. Effect of tumor subtype on survival and the graded prognostic assessment for patients with breast cancer and brain metastases. Int J Radiat Oncol Biol Phys 2012;82:2111-7.

151. Anders CK, Deal AM, Miller CR, et al. The prognostic contribution of clinical breast cancer subtype, age, and race among patients with breast cancer brain metastases. Cancer 2011;117:1602-11.

152. Niwińska A, Murawska M. New breast cancer recursive partitioning analysis prognostic index in patients with newly diagnosed brain metastases. Int J Radiat Oncol Biol Phys 2012;82:2065-71.

153. Chao ST, De Salles A, Hayashi M, et al. Stereotactic radiosurgery in the management of limited (1-4) brain metasteses: systematic review and international stereotactic radiosurgery society practice guideline. Neurosurgery 2018;83:345-53.

154. Tsao MN, Rades D, Wirth A, et al. Radiotherapeutic and surgical management for newly diagnosed brain metastasis (es): An American Society for Radiation Oncology evidence-based guideline. Pract Radiat Oncol 2012;2:210-25.

155. Hughes RT, Masters AH, McTyre ER, et al. Initial SRS for patients with 5 to 15 brain metastases: results of a multi-institutional experience. Int J Radiat Oncol Biol Phys 2019;104:1091-8.

156. Angelov L, Mohammadi AM, Bennett EE, et al. Impact of 2-staged stereotactic radiosurgery for treatment of brain metastases≥ 2 cm. J Neurosurg 2018;129:366-82.

157. Minniti G, Scaringi C, Paolini S, et al. Single-Fraction Versus Multifraction (3 x 9 Gy) Stereotactic Radiosurgery for Large (>2 cm) Brain Metastases: A Comparative Analysis of Local Control and Risk of Radiation-Induced Brain Necrosis. Int J Radiat Oncol Biol Phys 2016;95:1142-8.

158. Patchell RA, Tibbs PA, Walsh JW, et al. A randomized trial of surgery in the treatment of single metastases to the brain. N Engl J Med 1990;322:494-500.

159. Noordijk EM, Vecht CJ, Haaxma-Reiche H, et al. The choice of treatment of single brain metastasis should be based on extracranial tumor activity and age. Int J Radiat Oncol Biol Phys 1994;29:711-7.

160. Aoyama H, Shirato H, Tago M, et al. Stereotactic radiosurgery plus whole-brain radiation therapy vs stereotactic radiosurgery alone for treatment of brain metastases: a randomized controlled trial. JAMA 2006;295:2483-91.

161. Anders CK, Le Rhun E, Bachelot TD, et al. A phase II study of abemaciclib in patients (pts) with brain metastases (BM) secondary to HR+, HER2-metastatic breast cancer (MBC). American Society of Clinical Oncology; 2019.

162. Lin NU, Stein A, Nicholas A, et al. Planned interim analysis of PATRICIA: An open-label, single-arm, phase II study of pertuzumab (P) with high-dose trastuzumab (H) for the treatment of central nervous system (CNS) progression post radiotherapy (RT) in patients (pts) with HER2-positive metastatic breast cancer (MBC). American Society of Clinical Oncology; 2017.

163. Borges VF, Ferrario C, Aucoin N, et al. Efficacy results of a phase 1b study of ONT-380, a CNS-penetrant TKI, in combination with T-DM1 in HER2+ metastatic breast cancer (MBC), including patients (pts) with brain metastases. American Society of Clinical Oncology; 2016.

164. Lin NU, Freedman RA, Miller K, et al. Determination of the maximum tolerated dose (MTD) of the CNS penetrant tyrosine kinase inhibitor (TKI) tesevatinib administered in combination with trastuzumab in HER2+ patients with metastatic breast cancer (BC). American Society of Clinical Oncology; 2016.

165. Brown PD, Ballman KV, Cerhan JH, et al. Postoperative

stereotactic radiosurgery compared with whole brain radiotherapy for resected metastatic brain disease (NCCTG N107C/CEC· 3): a multicentre, randomised, controlled, phase 3 trial. Lancet Oncol 2017;18:1049-60.

166. Kayama T, Sato S, Sakurada K, et al. Effects of surgery with salvage stereotactic radiosurgery versus surgery with whole-brain radiation therapy in patients with one to four brain metastases (JCOG0504): a phase III, noninferiority, randomized controlled trial. J Clin Oncol 2018;JCO2018786186.

167. Routman DM, Yan E, Vora S, et al. Preoperative stereotactic radiosurgery for brain metastases. Front Neurol 2018;9:959.

168. Hospital GS. Local Treatment in ER-positive/HER2-negative Oligo-metastatic Breast Cancer (CLEAR). 2018. Available online: https://clinicaltrials.gov/ct2/show/NCT03750396

169. CCGP. GR. Trial of Superiority of Stereotactic Body Radiation Therapy in Patients With Breast Cancer. 2014. Available online: https://ClinicalTrials.gov/show/NCT02089100

170. Oncology NRG NCI. Standard of Care Therapy With or Without Stereotactic Radiosurgery and/or Surgery in Treating Patients With Limited Metastatic Breast Cancer. 2015. Available online: https://ClinicalTrials.gov/show/NCT02364557

171. Humanitas IC. Study on SBRT for Inoperable Lung and Liver Oligometastases From Breast Cancer. Study on SBRT for Inoperable Lung and Liver Oligometastases From Breast Cancer. Available online: https://www.clinicaltrials.gov/ct2/show/NCT02581670

172. Peter MacCallum Cancer Centre A. Pilot Study of Stereotactic Ablation for Oligometastatic Breast Neoplasia in Combination With the Anti-PD-1 Antibody MK-3475 (BOSTON II). 2014. Available online: https://clinicaltrials.gov/ct2/show/NCT02303366

173. Peter MacCallum Cancer Centre A. Stereotactic Radiation and Immunotherapy in Patients With Advanced Triple Negative Breast Cancer (AZTEC). 2018. Available online:

https://clinicaltrials.gov/ct2/show/NCT03464942

174. Antwerp CR. A Dose-escalation Trial of Stereotactic Ablative Body Radiotherapy for Non-spine Bone & Lymph Node Oligometastates (Destroy). 2018. Available online: https://clinicaltrials.gov/ct2/show/NCT03486431

175. British Columbia Cancer A LRCPC, Beatson Institute for Cancer Research S, et al. Stereotactic Ablative Radiotherapy for Comprehensive Treatment of Oligometastatic (1-3 Metastases) Cancer. 2019. Available online: https://ClinicalTrials.gov/show/NCT03862911

176. David P AUMCV, British Columbia Cancer - Centre for the N, et al. Stereotactic Ablative Radiotherapy for Comprehensive Treatment of 4-10 Oligometastatic Tumors. 2019. Available online: https://ClinicalTrials.gov/show/NCT03721341

177. Royal Marsden NHSFT IoCRU, National Health Service UK. Conventional Care Versus Radioablation (Stereotactic Body Radiotherapy) for Extracranial Oligometastases. 2016. Available online: https://ClinicalTrials.gov/show/NCT02759783

178. Center MSKC. Promise-004: Precision Radiation for OligoMetastatIc and MetaStatic DiseasE (PROMISE)-004: Consolidative Use of Radiotherapy to Block (CURB) Oligoprogression. 2019. Available online: https://www.clinicaltrials.gov/ct2/show/NCT03808662?cond=NCT03808662&draw=2&rank=1

179. Center MSKC. PROMISE-005: A Phase II Randomized Study Assessing the Efficacy of Stereotactic Body Radiotherapy (SBRT) in Patients With Oligometastatic Breast or Lung Cancer. 2019. Available online: https://www.clinicaltrials.gov/ct2/show/NCT03808337?cond=NCT03808337&draw=2&rank=1

180. Bauml JM, Mick R, Ciunci C, et al. Pembrolizumab After Completion of Locally Ablative Therapy for Oligometastatic Non-Small Cell Lung Cancer: A Phase 2 Trial. JAMA Oncol 2019;5:1283-90.

181. Florida Uo. Imaging the Patterns of Breast Cancer Early Metastases (BCMetPats). 2016. Available online: https://clinicaltrials.gov/ct2/show/NCT02706964